FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management

Fermenta granted process patent for plant-based Vitamin D3

Lonza appoints Jason Berndt as Head of Group Operations

Maria Soler Nunez appointed as Chief Quality Officer

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile

Sirio secures TGA GMP certification to support strategic growth in Australia

The Ma’anshan site approval covers pastilles, oral liquids, and powders

Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis